Bild:
Rubric:
Anna Thor. Photo: Jan Torbjörnsson
– I am very proud and honored to receive the scholarship from SFUO and Pfizer. Testicular cancer is a relatively uncommon disease that is easily overshadowed by larger diagnoses such as prostate cancer and bladder cancer, says Anna Thor, researcher at the Department of Clinical Science, Intervention and Technology, Karolinska Institutet, and assistant chief physician in urology at Karolinska University Hospital. She continues:
– My research concerns a young patient group with disseminated tumor disease, with the goal of tailoring therapy for the individual patient and reducing the risk of long-term side effects. MicroRNA is one piece of the puzzle, surgery another.
Anna Thor completed her dissertation in February 2025 on a thesis on microRNA and surgical treatment in testicular cancer. She is also responsible for the national highly specialized care mission retroperitoneal lymph node evacuation at Karolinska University Hospital in Huddinge.
– Through the collaboration between Sweden and Norway within SWENOTECA, we have a unique opportunity to conduct population-based research on this patient group. It feels meaningful to be able to contribute to more young men being able to live on, healthy, after their cancer. I also feel that there is a great interest in our data among other researchers in the world, which is of course extra motivating, concludes Anna Thor.
The scholarship will now support continued population-based research within the framework of the Swedish-Norwegian collaboration SWENOTECA.
The text is based on a press release from Pfizer.
